Next Article in Journal
Mechanistic Studies on the Dibenzofuran Formation from Phenanthrene, Fluorene and 9–Fluorenone
Next Article in Special Issue
Sequence Features of Drosha and Dicer Cleavage Sites Affect the Complexity of IsomiRs
Previous Article in Journal
Hologram QSAR Models of a Series of 6-Arylquinazolin-4-Amine Inhibitors of a New Alzheimer’s Disease Target: Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase-1A Enzyme
Previous Article in Special Issue
MiR-222 Targeted PUMA to Improve Sensitization of UM1 Cells to Cisplatin
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessReview
Int. J. Mol. Sci. 2015, 16(3), 5254-5270;

Development of Small RNA Delivery Systems for Lung Cancer Therapy

Division of Molecular and Cellular Medicine, National Cancer Center Research Institute, Tokyo 104-0045, Japan
Division of Respiratory Diseases, Department of Internal Medicine, Jikei University School of Medicine, Tokyo 105-8461, Japan
Author to whom correspondence should be addressed.
Academic Editor: Michael R. Ladomery
Received: 13 January 2015 / Revised: 27 February 2015 / Accepted: 4 March 2015 / Published: 6 March 2015
(This article belongs to the Special Issue RNA Interference)
Full-Text   |   PDF [956 KB, uploaded 9 March 2015]   |  


RNA interference (RNAi) has emerged as a powerful tool for studying target identification and holds promise for the development of therapeutic gene silencing. Recent advances in RNAi delivery and target selection provide remarkable opportunities for translational medical research. The induction of RNAi relies on small silencing RNAs, which affect specific messenger RNA (mRNA) degradation. Two types of small RNA molecules, small interfering RNAs (siRNAs) and microRNAs (miRNAs), have a central function in RNAi technology. The success of RNAi-based therapeutic delivery may be dependent upon uncovering a delivery route, sophisticated delivery carriers, and nucleic acid modifications. Lung cancer is still the leading cause of cancer death worldwide, for which novel therapeutic strategies are critically needed. Recently, we have reported a novel platform (PnkRNA™ and nkRNA®) to promote naked RNAi approaches through inhalation without delivery vehicles in lung cancer xenograft models. We suggest that a new class of RNAi therapeutic agent and local drug delivery system could also offer a promising RNAi-based strategy for clinical applications in cancer therapy. In this article, we show recent strategies for an RNAi delivery system and suggest the possible clinical usefulness of RNAi-based therapeutics for lung cancer treatment. View Full-Text
Keywords: RNAi; siRNA; miRNA; drug delivery system; lung cancer RNAi; siRNA; miRNA; drug delivery system; lung cancer

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Share & Cite This Article

MDPI and ACS Style

Fujita, Y.; Kuwano, K.; Ochiya, T. Development of Small RNA Delivery Systems for Lung Cancer Therapy. Int. J. Mol. Sci. 2015, 16, 5254-5270.

Show more citation formats Show less citations formats

Related Articles

Article Metrics

Article Access Statistics



[Return to top]
Int. J. Mol. Sci. EISSN 1422-0067 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top